Atai Life Sciences N.V.

NasdaqGM:ATAI

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

🧠 Mental Health

💊 Pharmaceuticals

Location

Germany

Market Cap

USD 522.65 M

Share Price

USD 2.48

Avg Daily Volume

1,975,701

Change (1 day)

6.44%

Change (1 year)

86.47%

Change (YTD)

86.47%

Atai Life Sciences N.V. Share Price Year-To-Date (YTD) return on June 20, 2025: 86.47%

Atai Life Sciences N.V. Share Price Year-To-Date (YTD) return is 86.47% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Atai Life Sciences N.V. 52-week low Share Price is USD 2.55 on June 20, 2025, which is 2.82% above the current Share Price.
Atai Life Sciences N.V. 52-week low Share Price is USD 1.06 on June 20, 2025, which is -57.26% below the current Share Price.
Atai Life Sciences N.V. average Share Price for the last 52 weeks is USD 1.51.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NasdaqGM: ATAI

Atai Life Sciences N.V.

CEO	Dr. Srinivas G. Rao M.D., Ph.D.
IPO Date	June 18, 2021
Location	Germany
Headquarters	Krausenstrasse 9-10
Employees	54
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 🧠 Mental Health 💊 Pharmaceuticals

Description

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.